WO2015064532A1 - Composé de morpholine - Google Patents

Composé de morpholine Download PDF

Info

Publication number
WO2015064532A1
WO2015064532A1 PCT/JP2014/078478 JP2014078478W WO2015064532A1 WO 2015064532 A1 WO2015064532 A1 WO 2015064532A1 JP 2014078478 W JP2014078478 W JP 2014078478W WO 2015064532 A1 WO2015064532 A1 WO 2015064532A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
methyl
phenyl
compound
substituted
Prior art date
Application number
PCT/JP2014/078478
Other languages
English (en)
Japanese (ja)
Inventor
明日香 河村
杉山　大介
千絵 杉田
隆之 北澤
中村　毅
Original Assignee
第一三共株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 第一三共株式会社 filed Critical 第一三共株式会社
Publication of WO2015064532A1 publication Critical patent/WO2015064532A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present invention relates to a compound or a pharmacologically acceptable salt thereof useful for the prevention or treatment of hyperphosphatemia or a disease associated with hyperphosphatemia.
  • Phosphorus is present in various forms in the body as an important component of the body such as DNA, RNA, or bone, and plays an important role in life support activities.
  • Phosphoric acid is mainly absorbed from food in the form of inorganic phosphorus in the digestive tract and excreted in the form of urine from the kidney (Non-patent Document 1). Blood phosphorus levels are maintained at a constant level through the action of vitamin D, parathyroid hormone (PTH), etc., and absorption in the digestive tract, renal excretion, and bone absorption and metabolism are controlled.
  • PTH parathyroid hormone
  • Non-patent Document 2 Excess phosphate binds to blood calcium and causes ectopic calcification in the cardiovascular system, which is regarded as a risk factor for cardiovascular diseases such as myocardial infarction (Non-patent Document 2).
  • Hyperphosphatemia secondarily causes hypocalcemia and, as a compensation, develops hyperparathyroidism characterized by elevated blood PTH levels, which is a sign of renal osteodystrophy. It is also a major factor.
  • hyperphosphatemia in patients with chronic renal failure decreases the QOL of chronic renal failure patients such as fractures and bone pain, and is a major factor in the death of chronic renal failure patients.
  • Non-patent Document 3 Calcium preparations have been shown to promote vascular calcification due to hypercalcemia (Non-patent Document 3), and polymer preparations have problems with compliance with medication taken by several g a day and digestive symptoms such as constipation and diarrhea (Non-Patent Document 4).
  • Non-Patent Document 5 metal salt preparations accumulate in the body (Non-Patent Document 5), and there are currently no sufficient therapeutic agents for treating hyperphosphatemia. It is said that sodium-dependent phosphate transporter expressed in small intestinal epithelial cells plays an important role in the absorption of inorganic phosphate in the digestive tract (Non-patent Document 6). Compounds that effectively inhibit the absorption of phosphorus from the gastrointestinal tract more efficiently than oral adsorbents, and improve the compliance with medications, digestive symptoms, and accumulation problems that were problematic in oral adsorbents It is expected to be possible. In view of the circumstances as described above, it is desired to develop a drug for preventing or treating new hyperphosphatemia or diseases associated with hyperphosphatemia. As compounds related to the present invention, there are compounds described in WO02011 / 136269, but the essential partial structure is different from the compounds of the present invention.
  • a compound useful as an active ingredient for the prevention and treatment of hyperphosphatemia or a pharmacologically acceptable salt thereof is provided.
  • the inventors of the present invention have completed the present invention as a result of intensive studies aimed at developing compounds useful as active ingredients for the prevention and treatment of hyperphosphatemia. That is, the present invention is as described below.
  • R 1 hydrogen atom, di-C1-C6 alkylamino group or C2-5 cycloalkylamino group
  • R 2 hydrogen atom, di-C1-C6 alkylamino group or C2-5 cycloalkylamino group
  • A: Single bond or -C ( O) -NH-
  • F: Single bond or -C ( O) -NH-
  • G a hydrogen atom, an optionally substituted aryl group, an optionally substituted aralkyl group, or an optionally substituted heterocyclic group
  • X CH or N
  • R 1 hydrogen atom, di-C1-C6 alkylamino group or C2-5 cycloalkylamino group
  • R 2 hydrogen atom, di-C1-C6 alkylamino group or C2-5 cycloalkylamino group
  • E aryl ring which may be substituted, or heterocyclic ring which may be substituted
  • X CH or N
  • R 1 is a hydrogen atom
  • R 2 is a diethylamino group, a piperidinyl group, or a pyrrolidinyl group
  • the aryl ring of the aryl ring which may be substituted is a benzene ring
  • the hetero ring of the heterocyclic ring which may be substituted is any ring selected from the following group, [2] or The compound according to [3] or a pharmacologically acceptable salt thereof.
  • Heterocycle group Azetidine, oxetane, thietane, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, tetrahydropyran, tetrahydrothiopyran, pyrrole, furan, thiophene, pyridine, imidazole, pyrazole, oxazole, thiazole, imidazoline, pyrazine, pyridazine, pyrimidine, morpholine, thiazine, Indole, isoindole, benzimidazole, purine, quinoline, isoquinoline, quinoxaline, cinnoline, pteridine, chromene, isochromene, dihydroindole, dihydroisoindole, dihydrobenzimidazole, dihydropurine, tetrahydroquinoline, tetrahydroiso
  • Substituent group Halogen atom, C1-C6 alkyl group, C3-C6 cycloalkyl group, halo C1-C6 alkyl group, C1-C6 alkoxycarbonyl group, C1-C6 alkylcarbonyl group [6]
  • the “optionally substituted group” on the optionally substituted aryl ring or the optionally substituted heterocyclic ring is any group selected from the following substituent group [4] or a pharmacologically acceptable salt thereof.
  • Substituent group Fluorine atom, chlorine atom, methyl group, ethyl group, C3-C6 cycloalkyl group, trifluoromethyl group, t-butoxycarbonyl group, 2,2-dimethylpropylcarbonyl group [7]
  • R 1 hydrogen atom, di-C1-C6 alkylamino group or C2-5 cycloalkylamino group
  • R 2 hydrogen atom, di-C1-C6 alkylamino group or C2-5 cycloalkylamino group
  • E aryl ring which may be substituted, or heterocyclic ring which may be substituted
  • G aryl group which may be substituted, or heterocyclic group which may be substituted
  • R 1 is a hydrogen atom
  • R 2 is a diethylamino group, a piperidinyl group, or a pyrrolidinyl group
  • the aryl ring of the aryl ring which may be substituted is a benzene ring
  • the heterocycle of the heterocyclic ring which may be substituted is any ring selected from the following group: [8] or [9] or a pharmacologically acceptable salt thereof.
  • Heterocycle group Azetidine, oxetane, thietane, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, tetrahydropyran, tetrahydrothiopyran, pyrrole, furan, thiophene, pyridine, imidazole, pyrazole, oxazole, thiazole, imidazoline, pyrazine, pyridazine, pyrimidine, morpholine, thiazine, Indole, isoindole, benzimidazole, purine, quinoline, isoquinoline, quinoxaline, cinnoline, pteridine, chromene, isochromene, dihydroindole, dihydroisoindole, dihydrobenzimidazole, dihydropurine, tetrahydroquinoline, tetrahydroiso
  • Substituent group Halogen atom, C1-C6 alkyl group, C3-C6 cycloalkyl group, C3-C6 cycloalkyloxy group, C3-C6 cycloalkylamino group, halo C1-C6 alkyl group, C1-C6 alkoxycarbonyl group, C1-C6 alkyl Carbonyl group [12]
  • the aryl ring which may be substituted or the heterocyclic ring which may be substituted is selected from the following substituent group, wherein “optionally substituted group” is selected: Or a pharmacologically acceptable salt thereof according to [10].
  • Substituent group Fluorine atom, chlorine atom, methyl group, ethyl group, cyclohexyl group, cyclohexyloxy group, cyclohexylamino group, trifluoromethyl group, t-butoxycarbonyl group, 2,2-dimethylpropylcarbonyl group
  • R 1 hydrogen atom, di-C1-C6 alkylamino group or C2-5 cycloalkylamino group
  • R 2 hydrogen atom, di-C1-C6 alkylamino group or C2-5 cycloalkylamino group
  • E aryl ring which may be substituted, or heterocyclic ring which may be substituted
  • G aryl group which may be substituted, aralkyl group which may be substituted, or heterocyclic group which may be substituted
  • R 1 is a hydrogen atom
  • R 2 is a diethylamino group, a piperidinyl group, or a pyrrolidinyl group
  • the compound or a pharmacologically acceptable salt thereof according to [13], wherein when R 2 is a hydrogen atom, R 1 is a diethylamino group,
  • the aryl ring of the aryl ring which may be substituted is a benzene ring
  • the heterocycle of the heterocyclic ring which may be substituted is any ring selected from the following group: [13] or the compound according to [14] or a pharmacologically acceptable salt thereof.
  • Heterocycle group Azetidine, oxetane, thietane, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, tetrahydropyran, tetrahydrothiopyran, pyrrole, furan, thiophene, pyridine, imidazole, pyrazole, oxazole, thiazole, imidazoline, pyrazine, pyridazine, pyrimidine, morpholine, thiazine, Indole, isoindole, benzimidazole, purine, quinoline, isoquinoline, quinoxaline, cinnoline, pteridine, chromene, isochromene, dihydroindole, dihydroisoindole, dihydrobenzimidazole, dihydropurine, tetrahydroquinoline, tetrahydroiso
  • Aralkyl group Benzyl, phenethyl, tetralinyl [17]
  • an optionally substituted aryl group (aryl ring), an optionally substituted aralkyl group, or an optionally substituted heterocyclic group (heterocycle) is “substituted.
  • Substituent group Halogen atom, C1-C6 alkyl group, C3-C6 cycloalkyl group, C3-C6 cycloalkyloxy group, C3-C6 cycloalkylamino group, halo C1-C6 alkyl group, C1-C6 alkoxycarbonyl group, C1-C6 alkyl Carbonyl group [18]
  • an optionally substituted aryl group (aryl ring), an optionally substituted aralkyl group, or an optionally substituted heterocyclic group (heterocycle) is “substituted.
  • [20] [1] A pharmaceutical composition comprising the compound according to any one of [19] or [19], or a pharmacologically acceptable salt thereof. [twenty one] [20] The pharmaceutical composition according to [20] for inhibiting phosphorus uptake. [twenty two] [20] The pharmaceutical composition according to [20] for prevention or treatment of hyperphosphatemia. [twenty three] Use of the compound according to any one of [1] to [19] or a pharmacologically acceptable salt thereof for producing a pharmaceutical composition for preventing or treating hyperphosphatemia. [twenty four] Use of the compound according to any one of [1] to [19] or a pharmacologically acceptable salt thereof for the prevention or treatment of hyperphosphatemia. [twenty five] [1] A method for preventing or treating hyperphosphatemia, comprising administering an effective amount of the compound or pharmacologically acceptable salt thereof according to any one of [19].
  • the compound having the general formula (I) of the present invention or a pharmaceutically acceptable salt thereof can be used as a preventive and / or therapeutic agent for hyperphosphatemia and the like.
  • R 1 hydrogen atom, di-C1-C6 alkylamino group or C2-5 cycloalkylamino group
  • R 2 hydrogen atom, di-C1-C6 alkylamino group or C2-5 cycloalkylamino group
  • A: Single bond or -C ( O) -NH-
  • F: Single bond or -C ( O) -NH-
  • G a hydrogen atom, an optionally substituted aryl group, an optionally substituted aralkyl group, or an optionally substituted heterocyclic group
  • X CH or N
  • R 1 and R 2 Di-C1-C6 alkylamino group: A group in which two C1-C6 alkyl groups are bonded to an amino group, such as a dimethylamino group, an ethylmethylamino group, a diethylamino group, and a dipropylamino group.
  • C1-C6 alkyl group A straight or branched group having 1 to 6 carbon atoms, for example, methyl group, ethyl group, propyl group, isopropyl group, n-butyl group, isobutyl group, t-butyl group, n-pentyl group, and n-hexyl group.
  • C2-5 cycloalkylamino group A cyclic group having 2 to 5 carbon atoms and containing one nitrogen atom in the ring, such as aziridine, azetidine, pyrrolidine, piperidine and the like.
  • aryl ring is a benzene ring or a naphthalene ring.
  • Groups that may be substituted on the aryl ring are halogen atoms, C1-C6 alkyl groups, C3-C6 cycloalkyl groups, halo C1-C6 alkyl groups, C1-C6 alkoxycarbonyl groups, C1-C6 alkylcarbonyl groups, and the like. . Note that, as is apparent from the structural formula showing the compound having the general formula (I), the aryl ring has a bond to which A and F are bonded.
  • a halogen atom is a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom.
  • the C1-C6 alkyl group and the C3-C6 cycloalkyl group are as defined above.
  • the halo C1-C6 alkyl group is a group in which a suitable number of halogen atoms are substituted on the C1-C6 alkyl group. For example, a trifluoromethyl group, a difluoromethyl group, a fluoromethyl group, 2,2,2-trifluoro An ethyl group and the like.
  • the C1-C6 alkoxycarbonyl group is a group in which an oxygen atom is bonded to a C1-C6 alkyl group and a carbonyl group is further bonded to the C1-C6 alkyl group, for example, a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, isopropyloxy group.
  • a C1-C6 alkylcarbonyl group is a group in which a carbonyl group is bonded to a C1-C6 alkyl group.
  • Heterocyclic ring which may be substituted:
  • a heterocyclic ring is a cyclic compound composed of two or more kinds of elements, and in the case of the present invention, it is composed of atoms selected from a carbon atom, an oxygen atom, a nitrogen atom, and a sulfur atom. It is a cyclic compound. It consists of a 3-6 membered ring and may be composed of multiple rings by condensing with other rings such as a benzene ring.
  • Examples of the group that may be substituted on the heterocycle include a halogen atom, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a halo C1-C6 alkyl group, a C1-C6 alkoxycarbonyl group, a C1-C6 alkylcarbonyl group, and the like. .
  • the heterocyclic ring has a bond that bonds to A and F.
  • the aryl group which may be substituted and the heterocyclic group which may be substituted are the same as the aryl ring which may be substituted and the heterocyclic ring which may be substituted. However, the aryl group which may be substituted and the heterocyclic group which may be substituted have a bond bonded to F.
  • Aralkyl group which may be substituted The aralkyl group is a group in which a methyl group is bonded to an aryl group, and examples thereof include a benzyl group, a phenethyl group, and a tetralinyl group.
  • Groups that may be aralkyl groups are halogen atoms, C1-C6 alkyl groups, C3-C6 cycloalkyl groups, halo C1-C6 alkyl groups, C1-C6 alkoxycarbonyl groups, C1-C6 alkylcarbonyl groups, etc.
  • the substituent is as defined above.
  • “Optionally substituted” is unsubstituted or substituted by 1 to 3.
  • the “pharmacologically acceptable salt” refers to a salt that can be used as a medicine. In the case of a compound having an acidic group or basic group, it can be converted into a “salt with a base” or an “acid addition salt” by reacting with a base or an acid, so that the salt is shown.
  • an alkali metal salt such as sodium salt, potassium salt or lithium salt
  • an alkaline earth metal salt such as magnesium salt or calcium salt
  • -Organic base salts such as methylmorpholine salt, triethylamine salt, tributylamine salt, diisopropylethylamine salt, dicyclohexylamine salt, N-methylpiperidine salt, pyridine salt, 4-pyrrolidinopyridine salt, picoline salt or glycine salt, lysine salt
  • Amino acid salts such as arginine salt, ornithine salt, glutamate and aspartate, and preferably alkali metal salts.
  • the pharmacologically acceptable “acid addition salt” of the compound is preferably a hydrohalide salt such as hydrofluoride, hydrochloride, hydrobromide, hydroiodide, nitrate, Inorganic acid salts such as perchlorates, sulfates, phosphates; lower alkane sulfonates such as methanesulfonate, trifluoromethanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfone Allyl sulfonates such as acid salts, organic acid salts such as acetate, malate, fumarate, succinate, citrate, ascorbate, tartrate, oxalate, maleate And amino acid salts such as glycine salt, lysine salt, arginine salt, ornithine salt, glutamate salt and aspartate salt, most preferably hydrohalide salt (especially hydrochloride).
  • the compound of the present invention or a pharmacologically acceptable salt thereof may absorb moisture, adhere to adsorbed water, or become a hydrate when left in the air or by recrystallization.
  • the present invention also includes such various hydrates, solvates and polymorphic compounds.
  • the compound of the present invention may have tautomers and geometric isomers depending on the type of substituent.
  • the compound of the present invention may be described in only one form of an isomer.
  • the present invention includes other isomers, separated isomers, or a mixture thereof. Is also included.
  • the compounds of the present invention may have asymmetric carbon atoms or axial asymmetry, and optical isomers based on these may exist.
  • the present invention also includes separated optical isomers or mixtures thereof.
  • the compound of the present invention also includes a label, that is, a compound in which one or more atoms of the compound are substituted with an isotope (eg, 2 H, 3 H, 13 C, 14 C, 35 S, etc.).
  • a label that is, a compound in which one or more atoms of the compound are substituted with an isotope (eg, 2 H, 3 H, 13 C, 14 C, 35 S, etc.).
  • the present invention also includes pharmacologically acceptable prodrugs of the compounds of the present invention.
  • a pharmacologically acceptable prodrug is a compound having a group that can be converted into an amino group, a hydroxyl group, a force ruboxyl group or the like by solvolysis or under physiological conditions. Examples of groups that form prodrugs include Prog. Med., 5, 2157-2161 (1985). Group described in the above.
  • the compound has an amino group
  • the amino group is acylated, alkylated or phosphorylated
  • the amino group is eicosanoylated, alanylated, pentylaminocarbonylated, (5-methyl-2-oxo-1,3-dioxolen-4- Yl) methoxycarbonylation, tetrahydrofuranylation, pyrrolidylmethylation, pivaloyloxymethylation, tert-butylated compounds, etc.
  • the compound has a hydroxyl group
  • Compounds in which the hydroxyl group is acylated, alkylated, phosphorylated, or borated (eg, the hydroxyl group is acetylated, palmitoylated, propanoylated, pivaloylated, succinylated, fumarylated, alanylated, dimethylaminomethylcarbonylated.
  • the compounds of the present invention and pharmacologically acceptable salts thereof can be produced by applying various known synthetic methods utilizing characteristics based on the basic structure or the type of substituent. At that time, depending on the type of functional group, it is effective in terms of production technology to replace the functional group with an appropriate protecting group (a group that can be easily converted into the functional group) at the stage from the raw material to the intermediate. There is a case. Examples of such protecting groups include protecting groups described in PGM Wuts and Green (TW Greene), Greene's Protective Groups in Organic Synthesis (4th edition, 2006). The reaction conditions may be appropriately selected according to the reaction conditions.
  • the desired compound after carrying out the reaction by introducing the protective group, the desired compound can be obtained by removing the protective group as necessary.
  • the prodrug of the compound of this invention can be manufactured by introduce
  • the reaction can be carried out by applying ordinary methods such as esterification, amidation, dehydration and the like.
  • the method for producing the compound is described below. However, the manufacturing method is not limited to the following method.
  • Method A is a method for producing compound (A6), which is a compound having general formula (I ′).
  • R 1 hydrogen atom, di-C1-C6 alkylamino group or C2-5 cycloalkylamino group
  • R 2 hydrogen atom, di-C1-C6 alkylamino group or C2-5 cycloalkylamino group
  • E aryl ring which may be substituted, or heterocyclic ring which may be substituted
  • X CH or N
  • Step A-1 can be activated by reacting (i) compound (A1) with oxalyl chloride and then reacting with compound (A2) to produce compound (A3) or (ii) compound (A1) and
  • compound (A3) is produced by reacting compound (A2) in the presence of a condensing agent.
  • a condensing agent for example, oxalyl chloride and a small amount of dimethylformamide are added to a methylene chloride solution of the compound (A1) at 0 ° C.-room temperature.
  • the compound (A2) and a base such as pyridine are added.
  • the reaction temperature is about room temperature -80 ° C
  • the reaction time is about 1-24 hours.
  • the reaction is carried out in a solvent in the presence of a condensing agent and a base.
  • the condensing agent used may be referred to as 1- [bis (dimethylamino) methylene] -1H-benzotriazolium-3-oxide hexafluorophosphate (hereinafter HBTU).
  • HATU 2- (1H-7-azabenzotriazol-1-yl) -1,1,3,3-tetramethyluronium hexafluorophosphate
  • HATU 4- (4 , 6-Dimethoxy-1,3,5-triazin-2-yl) -4-methylmorpholium chloride n-hydrate
  • DMT-MM 1-ethyl-3- (3 -Dimethylaminopropyl) carbodiimide hydrochloride
  • WSC or EDCI tertiary amines such as diisopropylethylamine, triethylamine and N-methylmorpholine.
  • Step A-2 is a step of producing the compound (A4) by reducing the nitro group of the compound (A3).
  • the reaction is performed in a solvent in the presence of a catalyst in a hydrogen atmosphere.
  • a catalyst examples include 10% palladium carbon and 10% palladium hydroxide.
  • the solvent used includes ethers such as tetrahydrofuran (hereinafter sometimes referred to as THF), esters such as ethyl acetate, Alcohols, such as ethanol, or those mixed solvents are mentioned.
  • THF tetrahydrofuran
  • esters such as ethyl acetate
  • Alcohols such as ethanol
  • the reaction pressure is normal pressure.
  • the reaction temperature is room temperature-60 ° C.
  • the reaction time is 1-24 hours.
  • this process can also be performed by heating and refluxing a reduction reaction with iron powder and ammonium chloride in an ethanol / water solvent.
  • Step A-3 is a step of producing the compound (A6) by condensing the compound (A4) and the compound (A5).
  • the reaction is carried out in a solvent in the presence of a condensing agent and a base.
  • a condensing agent used include HBTU, HATU, DMT-MM, and WSC.
  • the base used include tertiary amines such as diisopropylethylamine, triethylamine and N-methylmorpholine.
  • the solvent used include methylene chloride, ethylene dichloride, dimethylformamide, dimethylacetamide, methanol and the like.
  • the reaction temperature is about room temperature -80 ° C.
  • the reaction time is about 1-24 hours.
  • Method B is a method for producing compound (B6), which is a compound having the general formula (I ′′).
  • R 1 hydrogen atom, di-C1-C6 alkylamino group or C2-5 cycloalkylamino group
  • R 2 hydrogen atom, di-C1-C6 alkylamino group or C2-5 cycloalkylamino group
  • E aryl ring which may be substituted, or heterocyclic ring which may be substituted
  • G aryl group which may be substituted, or heterocyclic group which may be substituted
  • X CH or N
  • 2- Z halogen atom or trifluoromethanesulfonyloxy group
  • Step B-1 is a step of producing compound (B3) by combining compound (B1) and compound (B2).
  • the reaction is carried out in a solvent in the presence of a catalyst and a base.
  • the catalysts used are tetrakistriphenylphosphine palladium (0), bis (triphenylphosphine) palladium (II) dichloride, chloro (2-dicyclohexylphosphino-2 ', 4'6'-triisopropyl-1,1
  • Examples include catalysts composed of various transition metals and various ligands such as' -biphenyl) [2- (2'-amino-1,1'-biphenyl) palladium (II).
  • Step B-2 is a step of producing the compound (B4) by reducing the nitro group of the compound (B3), and is a step performed under the same conditions as Step A-2.
  • Step B-3 is a step of producing compound (B6) by condensing compound (B4) and compound (B5), and is a step performed under the same conditions as Step A-3.
  • Method C is a method for producing compound (C6), which is a compound having the general formula (I ′ ′′).
  • Step C-1 is a step of producing compound (C3) by combining compound (C1) and compound (C2), and is a step performed under the same conditions as Step B-1.
  • Step C-2 is a step of producing the compound (C4) by reducing the nitro group of the compound (C3), and is a step performed under the same conditions as Step A-2.
  • Step C-3 is a step of producing compound (C6) by condensing compound (C4) and compound (C5), and is a step performed under the same conditions as Step A-3.
  • the C ′ method is another method for producing the compound (C3) used in the C method.
  • Step C′-1 is a step of producing compound (C′3) by combining compound (C1) and compound (C′2), and is a step performed under the same conditions as Step B-1.
  • Step C'-2 is a step for producing compound (C)
  • Method D is a method of introducing a substituent of R 1 or R 2 during the production process when R 1 or R 2 is a di-C1-C6 alkylamino group or a C2-5 cycloalkylamino group It is.
  • R 1 or R 2 is a di-C1-C6 alkylamino group or a C2-5 cycloalkylamino group It is.
  • R 1 is a piperidinyl group and R 2 is a hydrogen atom
  • Step D-1 is a step of producing compound (A3) by binding compound (D1) and piperidine.
  • the reaction is performed in a solvent.
  • the solvent used is preferably an ether such as THF.
  • the reaction temperature is room temperature-80 ° C.
  • the reaction time is about 1-24 hours.
  • Step D′-1 is a step of producing compound (B3) by binding compound (D′ 1) and piperidine, and is a step performed under the same conditions as Step D-1.
  • the reaction is performed in a solvent.
  • the solvent used is preferably an ether such as THF.
  • the reaction temperature is room temperature-80 ° C.
  • the reaction time is about 1-24 hours.
  • the compound produced by the above method can be isolated and purified by a known method such as extraction, precipitation, distillation, chromatography, fractional recrystallization, recrystallization and the like.
  • optical isomers exist when a compound or an intermediate of production has an asymmetric carbon. These optical isomers can be isolated and purified by conventional methods such as fractional recrystallization (salt resolution) recrystallizing with an appropriate salt and column chromatography.
  • References for a method for resolving optical isomers from racemates include “Enantiomers, Racemates and Resolution, John Wiley And Sons, Inc.” by J. Jacques et al.
  • Rat 33 P phosphate oral loading test small intestine phosphate absorption inhibition test
  • a solvent such as 0.5% methylcellulose
  • Oral gavage was performed to achieve kg.
  • the solvent was administered at 5 mL / kg.
  • Dosage form administration is oral by tablet, pill, force pusher, granule, powder, liquid, etc., or injection of joint meat, vein meat, intramuscular, suppository, eye drops, eye ointment, transdermal Any form of parenteral administration such as a liquid, an ointment, a transdermal patch, a transmucosal liquid, a transmucosal patch, and an inhalant may be used.
  • Solid compositions for oral administration include Tablets, powders, or granules are used.
  • one or more active ingredients are combined with at least one inert excipient such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinyl pip. Mixed with redone and / or magnesium aluminate metasilicate.
  • the composition contains an inert additive, for example, a lubricant such as magnesium stearate, a disintegrant such as sodium ruboxymethyl starch, a stabilizer and a solubilizing agent according to a conventional method. Also good. If necessary, tablets or pills may be coated with a sugar coating or a film of a gastric or enteric substance.
  • Liquid compositions for oral administration are: Contains pharmaceutically acceptable emulsions, solutions, suspensions, syrups or elixirs, and contains generally used inert diluents such as purified water or ethanol.
  • the liquid composition may contain solubilizers, wetting agents, auxiliaries such as suspending agents, sweeteners, flavors, fragrances and preservatives in addition to the inert diluent.
  • Injection for parenteral administration Contains sterile aqueous or non-aqueous solutions, suspensions or emulsions.
  • the aqueous solvent include distilled water for injection or physiological saline.
  • the non-aqueous solvent include propylene glycol, polyethylene glycol or vegetable oil such as olive oil, alcohols such as ethanol, or polysorbate 80.
  • Such compositions may further contain isotonic agents, preservatives, wetting agents, emulsifiers, dispersants, stabilizers, or solubilizing agents. These are sterilized by, for example, filtration through a bacteria-retaining filter, blending of a bactericidal agent or irradiation. These can also be used by producing a sterile solid composition and dissolving or suspending it in sterile water or a sterile solvent for injection before use.
  • ointments As an external preparation, Includes ointments, plasters, creams, jellies, poultices, sprays, lotions, eye drops, eye ointments and the like.
  • ointment bases include commonly used ointment bases, lotion bases, aqueous or non-aqueous solutions, suspensions, emulsions, and the like.
  • ointment or lotion bases include polyethylene glycol, propylene glycol, white petrolatum, white beeswax, polyoxyethylene hydrogenated castor oil, glyceryl monostearate, stearyl alcohol, cetyl alcohol, lauromacrogol, sorbitan sesquioleate, etc. Can be mentioned.
  • a transmucosal agent such as an inhalant or a nasal agent is used in a solid, liquid or semi-solid form, and can be produced according to a conventionally known method.
  • known excipients, and further pH adjusters, preservatives, surfactants, lubricants, stabilizers, thickeners and the like may be appropriately added.
  • an appropriate device for inhalation or insufflation can be used.
  • a known device or nebulizer such as a metered dose inhalation device, the compound is administered as a solution or suspension alone or as a powder in a formulated mixture, or in combination with a pharmaceutically acceptable carrier. be able to.
  • the dry powder inhaler or the like may be used for single or multiple administrations, and a dry powder or a powder-containing power capsule can be used. Alternatively, it may be in the form of a pressurized aerosol spray using a suitable gas such as a suitable propellant such as chlorofluoroalcohol, hydrofluoroalcohol or carbon dioxide.
  • a suitable gas such as a suitable propellant such as chlorofluoroalcohol, hydrofluoroalcohol or carbon dioxide.
  • the daily dose in general, in the case of oral administration, is about 0.001-100 mg / kg, preferably O.1-30 mg / kg, more preferably 0.1-10 mg / kg per body weight. Or do it in two or more divided doses.
  • the daily dose is suitably about 0.0001-10 mg / kg per body weight, and is administered once or divided into multiple doses per day.
  • a transmucosal agent about 0.001-100 mg / kg per body weight is administered once a day or divided into multiple times.
  • the dose is appropriately determined according to individual cases in consideration of symptoms, age, sex, and the like.
  • the compound of the present invention can be used in combination with various therapeutic agents or preventive agents for diseases for which the compound is considered to be effective.
  • the combination may be administered simultaneously, separately separately, or at desired time intervals.
  • the simultaneous administration preparation may be a compounding agent or may be separately formulated.
  • (Formulation Example 1) Powder A powder is obtained by mixing 5 g of the compound of the present invention, 895 g of lactose and 100 g of corn starch with a blender. (Formulation Example 2) Granules After mixing 5 g of the compound of the present invention, 865 g of lactose and 100 g of low-substituted hydroxypropylcellulose, 300 g of a 10% hydroxypropylcellulose aqueous solution is added and kneaded. This is granulated using an extrusion granulator and dried to obtain granules.
  • Example 4 N- [4-Bromo-1- [3- (trifluoromethyl) phenyl] pyrazol-3-yl] -5-fluoro-2-nitro-benzamide
  • Example 4 was prepared in the same manner as Example 2 (2c). From the compound (1.16 g) obtained in (4a), 760 mg (38%) of the title compound was obtained as a white solid.
  • Example 5 N5-methyl-N5- (2-morpholinoethyl) -N3- (4- (1-piperidyl) -2- ⁇ [1- (2-pyridyl) -3- (trifluoromethyl) pyrazol-4-yl] carbamoyl ⁇ Phenyl) pyridine-3,5-dicarboxamide
  • Example 5 N5-methyl-N5- (2-morpholinoethyl) -N3- (4- (1-piperidyl) -2- ⁇ [1- (2-pyridyl) -3- (trifluoromethyl) pyrazol-4-yl] carbamoyl ⁇ Phenyl) pyridine-3,5-dicarboxamide
  • Example 6 5- [Methyl (2-morpholinoethyl) sulfamoyl] -N- (4- (1-piperidyl) -2- ⁇ [1- (2-pyridyl) -3- (trifluoromethyl) pyrazol-4-yl] carbamoyl ⁇ Phenyl) pyridine-3-carboxamide
  • Example 6 5- [Methyl (2-morpholinoethyl) sulfamoyl] -N- (4- (1-piperidyl) -2- ⁇ [1- (2-pyridyl) -3- (trifluoromethyl) pyrazol-4-yl] carbamoyl ⁇ Phenyl) pyridine-3-carboxamide
  • reaction mixture was stirred at 90 ° C. for 6 hours, diluted with water and extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate and saturated brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography to give 592 mg (100%) of the title compound as a colorless solid.
  • reaction mixture was stirred at room temperature for 20 hours, diluted with water and extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate and saturated brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography to obtain 182 mg of the title compound as a yellow solid in a quantitative yield.
  • the reaction mixture was stirred at 130 ° C. for 1 hour under microwave irradiation.
  • the reaction mixture was cooled to room temperature, diluted with water and extracted with ethyl acetate, the organic layer was dried over magnesium sulfate, filtered and concentrated.
  • the residue was purified by column chromatography to obtain 48 mg (25%) of the title compound as a white solid.
  • the reaction mixture was stirred at room temperature for 4 hours, diluted with saturated aqueous sodium hydrogen carbonate solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography to obtain 184 mg (quantitative yield) of the title compound as a yellow oil.
  • the reaction mixture was stirred at 70 ° C. for 1 hour.
  • the reaction solution was poured into water and extracted with ethyl acetate.
  • the organic layer was washed with saturated brine, dried over sodium sulfate, filtered and concentrated.
  • the residue was purified by column chromatography to obtain 1.2 g (77%) of the title compound as a colorless solid.
  • Example 15b 4- [5- (Cyclohexyloxy) pyrazin-2-yl] aniline Similarly to Example 11 (11b), the compound (400.0 mg) obtained in Example 15 (15a) and 4- (4,4,5 , 5-Tetramethyl-1,3,2-dioxaborolan-2-yl) aniline (340.9 mg) gave 198.7 mg (47%) of the title compound as a pale yellow solid.
  • Example 17c N1- [2-[[4- [2- (Cyclohexylamino) pyrimidin-5-yl] phenyl] carbamoyl] -4- (1-piperidyl) phenyl] -N3-methyl-N3- (2-morpholinoethyl) benzene -1,3-dicarboxamide Similar to Example 11 (11c) and (11d), the compound obtained in Example 17 (17b) (104.2 mg) and 5-fluoro-2-nitrobenzoic acid (109.1 mg) Gave 99.5 mg (34%, 4 steps) of the title compound as a yellow oil.
  • Example 21 N- [4- [6- (cyclohexyloxy) -3-pyridyl] phenyl] -2-[[3- [methyl (2-morpholinoethyl) sulfamoyl] benzoyl] amino] -5- (1-piperidyl) benzamide
  • the compound (139.9 mg) obtained in Example 12 (12b) and the compound (164.7 mg) obtained in Reference Example 1 were used to give 208.1 mg (90%) of the title compound.
  • the reaction mixture was poured into brine and extracted with ethyl acetate.
  • the extract was washed successively with water and saturated brine, and dried over anhydrous sodium sulfate.
  • the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography.
  • the solvent was distilled off under reduced pressure, water was added to the residue, and the resulting solid was collected by filtration, washed with water, and dried with a vacuum pump to obtain 136.9 mg (53%) of the title compound as a pale yellow solid.
  • Example 26c tert-Butyl 2- ⁇ 2-Amino- (5-piperidin-1-yl) phenyl ⁇ -7,8-dihydro-1,6-naphthyridine-6 (5H) -carboxylate obtained in Example 26 (26d)
  • the title compound (0.25 g, 89%) was obtained as a pale yellow oil in the same manner as in Example 23 (23c) using the compound (0.30 g) and 10% palladium-carbon (0.050 g).
  • reaction mixture was further stirred at room temperature for 1 hour, diluted with saturated aqueous sodium hydrogen carbonate solution, and extracted with DCM. The organic layer was dried over magnesium sulfate, filtered and concentrated. The residue was purified by column chromatography to obtain 1.91 g (54%) of the title compound as a colorless oil.

Abstract

L'objectif de la présente invention est de prévenir ou de traiter l'hyperphosphatémie ou une maladie associée à l'hyperphosphatémie. Pour atteindre cet objectif, l'invention concerne un composé répondant à la formule générale (I), ou un sel pharmaceutiquement acceptable de celui-ci. [Dans la formule, R1 représente un atome d'hydrogène, etc., R2 représente un atome d'hydrogène, etc., A représente une simple liaison, etc., E représente un cycle benzène, etc., G représente un atome d'hydrogène, etc., X représente CH, etc., et Y représente -C(=O)-, etc.]
PCT/JP2014/078478 2013-10-30 2014-10-27 Composé de morpholine WO2015064532A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013225099 2013-10-30
JP2013-225099 2013-10-30

Publications (1)

Publication Number Publication Date
WO2015064532A1 true WO2015064532A1 (fr) 2015-05-07

Family

ID=53004135

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/078478 WO2015064532A1 (fr) 2013-10-30 2014-10-27 Composé de morpholine

Country Status (2)

Country Link
TW (1) TW201607925A (fr)
WO (1) WO2015064532A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016171240A1 (fr) * 2015-04-24 2016-10-27 第一三共株式会社 Procédé de production d'un composé d'acide dicarboxylique
CN106316987A (zh) * 2015-07-03 2017-01-11 江苏恒瑞医药股份有限公司 苯甲酰胺类衍生物、其制备方法及其在医药上的应用
CN113473989A (zh) * 2019-02-27 2021-10-01 米伦纽姆医药公司 Sumo活化酶抑制剂和检查点抑制剂的施用
CN114621135A (zh) * 2020-12-11 2022-06-14 上海拓界生物医药科技有限公司 一种lpa1小分子拮抗剂

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011136269A1 (fr) * 2010-04-28 2011-11-03 アステラス製薬株式会社 Composé de tétrahydrobenzothiophène
WO2012006475A1 (fr) * 2010-07-07 2012-01-12 Ardelyx, Inc. Composés et procédés pour l'inhibition du transport de phosphate
WO2013062065A1 (fr) * 2011-10-27 2013-05-02 アステラス製薬株式会社 Dérivé de n-thiényl benzamide substitué avec un aminoalkyle
JP2013530247A (ja) * 2010-07-07 2013-07-25 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
JP2013533886A (ja) * 2010-07-07 2013-08-29 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
WO2013129435A1 (fr) * 2012-02-28 2013-09-06 協和発酵キリン株式会社 Dérivé de thiophène fusionné
JP2013544753A (ja) * 2010-07-07 2013-12-19 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011136269A1 (fr) * 2010-04-28 2011-11-03 アステラス製薬株式会社 Composé de tétrahydrobenzothiophène
WO2012006475A1 (fr) * 2010-07-07 2012-01-12 Ardelyx, Inc. Composés et procédés pour l'inhibition du transport de phosphate
JP2013530247A (ja) * 2010-07-07 2013-07-25 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
JP2013533886A (ja) * 2010-07-07 2013-08-29 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
JP2013544753A (ja) * 2010-07-07 2013-12-19 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
WO2013062065A1 (fr) * 2011-10-27 2013-05-02 アステラス製薬株式会社 Dérivé de n-thiényl benzamide substitué avec un aminoalkyle
JP2013107880A (ja) * 2011-10-27 2013-06-06 Astellas Pharma Inc Ｎ−チエニルベンズアミド誘導体
WO2013129435A1 (fr) * 2012-02-28 2013-09-06 協和発酵キリン株式会社 Dérivé de thiophène fusionné

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016171240A1 (fr) * 2015-04-24 2016-10-27 第一三共株式会社 Procédé de production d'un composé d'acide dicarboxylique
JPWO2016171240A1 (ja) * 2015-04-24 2018-02-15 第一三共株式会社 ジカルボン酸化合物の製法
CN106316987A (zh) * 2015-07-03 2017-01-11 江苏恒瑞医药股份有限公司 苯甲酰胺类衍生物、其制备方法及其在医药上的应用
CN106316987B (zh) * 2015-07-03 2020-11-17 江苏恒瑞医药股份有限公司 苯甲酰胺类衍生物、其制备方法及其在医药上的应用
CN113473989A (zh) * 2019-02-27 2021-10-01 米伦纽姆医药公司 Sumo活化酶抑制剂和检查点抑制剂的施用
CN113473989B (zh) * 2019-02-27 2024-03-08 武田药品工业株式会社 Sumo活化酶抑制剂和检查点抑制剂的施用
CN114621135A (zh) * 2020-12-11 2022-06-14 上海拓界生物医药科技有限公司 一种lpa1小分子拮抗剂
CN114621135B (zh) * 2020-12-11 2024-01-30 上海拓界生物医药科技有限公司 一种lpa1小分子拮抗剂

Also Published As

Publication number Publication date
TW201607925A (zh) 2016-03-01

Similar Documents

Publication Publication Date Title
AU2019264253B2 (en) Factor XIIa inhibitors
EP2935249B1 (fr) Inhibiteurs d'autotaxine
WO2015108038A1 (fr) Composé d'éthylène glycol
KR101981347B1 (ko) 구아니디노벤조산 화합물
WO2014020350A1 (fr) Antagonistes du récepteur par2
JP2009507001A (ja) 因子Ｘａ阻害剤としての新規なシクロアルカンカルボキシアミド
KR20110127158A (ko) Ｃｏｐｄ의 치료에 유용한 5-피라졸릴-2-피리돈 유도체의 토실레이트 염
TWI666196B (zh) 胍基苯甲酸酯化合物
JP5774253B2 (ja) ジカルボン酸化合物
WO2015064532A1 (fr) Composé de morpholine
TWI686387B (zh) 二羧酸化合物之鹽
WO2006043510A1 (fr) Dérivé d’ester et applications pharmaceutiques dudit dérivé
US10653682B2 (en) Oxadiazoles and thiadiazoles as TGF-β inhibitors
EP2805705B1 (fr) Emballage comprenant des unités d'administration des sels de sodium de l'acide (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionique
EA045768B1 (ru) Производные n-метил, n-(6-(метокси)пиридазин-3-ил)амина в качестве модуляторов аутотаксина (atx) для лечения воспалительных заболеваний дыхательных путей или фиброзных заболеваний
JP2015003876A (ja) トリアゾール化合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14859191

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14859191

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP